pegylated basal insulin (AB101) / Rezolute - LARVOL DELTA

Study to Investigate the Effect of AB-101 in Breast Cancer Survivors (clinicaltrials.gov) - P1; N=3; Completed; Sponsor: Applied Biology, Inc.; Recruiting ➔ Completed; N=35 ➔ 3

Enrollment change • Trial completion

[VIRTUAL] A first in human, single ascending dose study to assess the safety and tolerability, pharmacokinetics, and pharmacodynamics of AB101 in subjects with type 1 diabetes (EASD 2021) - "Overall, single SC doses of AB101 in patients with T1DM were safe and well tolerated, with no evidence of sudden insulin release. Administration of AB101 resulted in slow onset and sustained insulin levels and activity for more than seven days with dose-dependent improvements in glycemic variability, background insulin requirements, and glucose disposal. However, at active doses, the necessary dose volume was greater than anticipated, and delayed or variable kinetics was observed."

Clinical • P1 data • PK/PD data • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

[VIRTUAL] Study of Genetic Variability, Occurrence, Potential Reservoirs and Vectors of Strawberry Polerovirus 1 in the Czech Republic (WMF 2021) - "Their comparisons, including the Canadian AB4101 isolate SPV 1, showed high levels of nucleotide identities (97 - 100%, ~ 1.7 kb region). The other non-strawberry SPV 1 hosts were not detected. The survey revealed the high genetic identity among Czech and American SPV 1 isolates, virus occurrence in 22% of tested strawberry plants, and determined possible insect vectors."

Infectious Disease

Specific egg yolk immunoglobulin as a promising non-antibiotic biotherapeutic product against Acinetobacter baumannii pneumonia infection. (PubMed, Sci Rep) - "Specific IgYs showed different protectivity against A. baumannii AbI101 in the murine pneumonia model...The lowest protection was observed in mice received IgYs raised against the combination of rOmpA and rOmp34. In conclusion, specific IgYs against OmpA, Omp34, and IWC of A. baumannii could serve as novel biotherapeutics against A. baumannii pneumonia."

Journal • Infectious Disease • Pneumonia • Respiratory Diseases

AB-101 as Monotherapy and In Combination With Rituximab in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - P1/2; N=60; Recruiting; Sponsor: Artiva Biotherapeutics, Inc.; Not yet recruiting ➔ Recruiting

Clinical • Combination therapy • Enrollment open • Monotherapy • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

AB-101 as Monotherapy and In Combination With Rituximab in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - P1/2; N=60; Not yet recruiting; Sponsor: Artiva Biotherapeutics, Inc.

Clinical • Combination therapy • Monotherapy • New P1/2 trial • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology